Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice
Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice
复制标题
柯萨奇病毒 B5 病毒样颗粒疫苗在小鼠体内表现出比灭活疫苗更强的免疫原性和免疫保护作用
DOI：
10.1016/j.vaccine.2021.07.095
复制
发表时间：
2021-09-14
期刊：
影响因子：
5.5
通讯作者：
Liu, Qiliang
中科院分区：
文献类型：
--
作者：
Zhang, Ning;Zheng, Tianpeng;Liu, Qiliang
柯萨奇病毒B 5群（Coxsackievirus 5 group，CVB 5）是引起手足口病（Handfoot and mouth disease，HFMD）、无菌性脑膜炎等疾病的主要病原体之一，目前尚无特效药物和疫苗，安全有效的CVB 5疫苗对控制该病具有重要价值。本研究利用杆状病毒表达系统在Sf 9细胞中共表达CVB 5 P1前体蛋白和3CD蛋白酶。P1经3CD处理后自组装成CVB 5病毒样颗粒（VLP）。SDS-PAGE和Westernblotting均能检测到CVB 5的VP 1和VP 3衣壳蛋白。透射电子显微镜显示CVB 5 VLP是直径约30 nm的球形颗粒，模拟野生型CVB 5病毒。结果表明，CVB 5 VLP诱导的总IgG和中和抗体均高于灭活疫苗。更重要的是，CVB 5 VLP通过被动免疫对CVB 5攻击的乳鼠产生完全保护，而灭活疫苗的保护效率仅为80%。CVB 5 VLP疫苗能保护乳鼠肢体肌肉、脑和心脏组织免受CVB 5诱导的损伤。这些结果表明CVB 5 VLP疫苗具有更强的免疫原性，比灭活CVB 5疫苗提供更强的免疫保护，表明CVB 5 VLP有望成为未来的CVB 5疫苗候选物。(c)2021作者由爱思唯尔有限公司出版。这是一篇在CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Coxsackievirus B group 5 (CVB5) represents one of the major pathogens that cause diseases such as hand, foot and mouth disease (HFMD) and aseptic meningitis et al. Currently, no specific drugs and vaccines are available, and a safe and effective CVB5 vaccine is of great value for control of the diseases. In this study, CVB5 P1 precursor and 3CD protease were co-expressed in Sf9 cells by using a baculovirus expression system. The P1 was processed by 3CD and self-assembled into CVB5 virus-like particles (VLPs). VP1 and VP3 capsid proteins of CVB5 could be detected by SDS-PAGE and Western blotting. Transmission electron microscopy revealed that the CVB5 VLPs were spherical particles with a diameter of about 30 nm, mimicking wild-type CVB5 virus. Our study showed that the total IgG and neutralizing antibodies induced by CVB5 VLPs were higher than those induced by inactivated vaccine. More importantly, the CVB5 VLPs conferred full protection to the CVB5-challenged suckling mice via passive immunity while protection efficiency of the inactivated vaccine was only 80%. The CVB5 VLPs vaccine could protect the limb muscles, brain, and heart tissues of suckling mice from CVB5-induced damage. These results demonstrated that the CVB5 VLPs vaccine possessed stronger immunogenicity and provided more robust immunoprotection than the inactivated CVB5 vaccine, suggesting that the CVB5 VLPs promise to be a CVB5 vaccine candidate in future. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).